Business / Finance RSS Feed - Business / Finance

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs. [More]
Oventus reports early revenues, establishes platform for accelerated growth

Oventus reports early revenues, establishes platform for accelerated growth

Medical device sleep apnoea and snoring disorder company Oventus Medical Ltd. releases its first 4E. The company has established a platform for accelerated growth following a successful IPO raising $12 million and is reporting encouraging early revenue. [More]
mOm raises £630,000 in seed funding to develop revolutionary infant incubator

mOm raises £630,000 in seed funding to develop revolutionary infant incubator

mOm has raised £630,000 in seed funding from a prominent set of investors to further develop its revolutionary baby incubator. Led by MaSa Partners (a US-based impact fund), investors include Holly Branson (as part of the Virgin Group), Lord Rumi Verjee (as part of the The Rumi Foundation), Continuity Capital, Dr. Joshua Boger, Johannes Heine, Rockspring, and The London Co Investment Fund. [More]
Chris Molloy appointed new CEO of Medicines Discovery Catapult

Chris Molloy appointed new CEO of Medicines Discovery Catapult

The Medicines Discovery Catapult has appointed its first Chief Executive Officer. Chris Molloy, who has more than 25 years’ experience in the international life science industry, will lead the MDC in developing new approaches for the discovery and early development of new medicines. [More]
W. Nuhsbaum to provide Leica microscopy and digital imaging solutions in Tennessee

W. Nuhsbaum to provide Leica microscopy and digital imaging solutions in Tennessee

Leica Microsystems, a technology leader with a 160-year history of providing best-in-class precision microscopy and digital micro-imaging solutions, announces a strategic expansion in its market representation in Tennessee. [More]
Cambridge Consultants creates new Evonetix spin-out to focus on accurate DNA synthesis

Cambridge Consultants creates new Evonetix spin-out to focus on accurate DNA synthesis

A breakthrough in DNA synthesis has led to the creation of a new spin-out company from the stable of product design and development firm Cambridge Consultants. [More]
CSIRO's partner Oventus Medical listed on ASX after raising $12 million

CSIRO's partner Oventus Medical listed on ASX after raising $12 million

CSIRO partner Oventus Medical Ltd has today listed on the Australian Securities Exchange raising $12m. [More]
KNAUER named among TOP 100 innovative medium-sized businesses in Germany for fifth time

KNAUER named among TOP 100 innovative medium-sized businesses in Germany for fifth time

During the 3rd German Summit for medium-sized businesses at UNESCO World Heritage Zeche Zollverein in Essen, mentor Ranga Yogeshwar awarded this year’s Top-Innovators on June 24. [More]
Opioid funding bill should address greater access to balanced pain management

Opioid funding bill should address greater access to balanced pain management

The Alliance for Balanced Pain Management (AfBPM) made the following statement on the Obama administration’s plan to curb the opioid addiction crisis, which was released this morning as Congress prepares to tackle funding for related programs. [More]
Osprey Medical announces record sales for medical device

Osprey Medical announces record sales for medical device

Osprey Medical has announced record sales results for the second quarter of CY2016, reflecting strong adoption by physicians and hospitals of Osprey’s technology protecting patients from the harmful effects of X-ray dye. [More]
Minoryx Therapeutics initiates phase 1 clinical trial of MIN-102

Minoryx Therapeutics initiates phase 1 clinical trial of MIN-102

Minoryx Therapeutics, a drug development company specialized in the discovery and development of new drugs for orphan diseases, today announces the initiation of its first-in-man Phase 1 clinical trial for its lead compound MIN-102. [More]
RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, together with IntelGenx Corp., a Canadian drug delivery company focused on oral drug delivery, today announced the signing of an exclusive license agreement with Grupo JUSTE S.A.Q.F (“Grupo JUSTE”), for the commercialization of RIZAPORT™ in Spain, and a right of first refusal for additional territories. RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. [More]

BioTek Instruments expands in Canada

BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country. [More]
MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys AG announced that it has received a milestone payment from Novartis in connection with the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The antibody will be tested in the field of prevention of thrombosis. This is the twelfth therapeutic antibody based on MorphoSys's technologies that Novartis is evaluating in clinical trials. Financial details were not disclosed. [More]
Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis). [More]
CDC invests in Donator’s unique heat stabilization technology

CDC invests in Donator’s unique heat stabilization technology

Denator, the Swedish-based biotechnology company specialized in biological sample preparation technologies announced today that the Center for Disease Control and Prevention, Atlanta, had made a major purchase of its proprietary heat stabilization technology Stabilizor T1™. [More]
Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway. [More]
Proscia completes $1M seed round of financing to advance cancer diagnosis, treatment

Proscia completes $1M seed round of financing to advance cancer diagnosis, treatment

Proscia Inc., a data solutions provider for digital pathology, announced today the completion of its $1M seed round of financing. [More]
Illumina signs initial customer deals for new Global Screening Array

Illumina signs initial customer deals for new Global Screening Array

Illumina, Inc. today announced that it has signed deals with 12 customers for its new Infinium Global Screening Array (GSA). [More]
David Gandy becomes new ambassador for Vitabiotics Wellman

David Gandy becomes new ambassador for Vitabiotics Wellman

Known for his passion for fitness and for the championing of top British brands, David Gandy is the new ambassador for Vitabiotics Wellman. [More]
Advertisement
Advertisement